Latest Articles
DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer - OncLive
DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer OncLive
Published: Nov. 26, 2025, 7:03 p.m.
DUO-E Post Hoc Analysis Suggests Potential for Biomarker-Optimized pMMR Endometrial Cancer Management - OncLive
DUO-E Post Hoc Analysis Suggests Potential for Biomarker-Optimized pMMR Endometrial Cancer Management OncLive
Published: May 6, 2025, 2:01 p.m.
Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups - OncLive
Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups OncLive
Published: March 17, 2025, 5:39 p.m.
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer - OncLive
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer OncLive
Published: March 15, 2025, 4:52 p.m.
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer - OncLive
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer OncLive
Published: Dec. 3, 2024, 5:11 p.m.
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer - OncLive
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer OncLive
Published: July 1, 2024, 7 a.m.
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer - OncLive
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer OncLive
Published: April 8, 2024, 7 a.m.
Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer - OncLive
Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer OncLive
Published: April 2, 2024, 7 a.m.
Link copied to clipboard!